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IMPAK PROGRAM PENJAGAAN ASMA KE ATAS PROSES DAN 
HASILAN KOS DI KALANGAN KANAK-KANAK BERPENYAKIT ASMA 
DI DUA BUAH HOSPITAL UTAMA DALAM MALAYSIA 
 
ABSTRAK 
 
PENGENALAN: Penyakit asma dalam kanak-kanak merupakan salah satu daripada 
penyakit kronik yang umum. Akibat prevalensnya yang tinggi, penyakit asma 
menyebabkan beban ekonomi yang agak besar kepada sistem penjagaan kesihatan 
dan masyarakat. Pengurusan secara optima boleh mengawal gangguan ini dan 
pelbagai intervensi telah dilakukan berdasarkan saranan daripada beberapa 
garispanduan amalan klinikal (CPG). Meskipun terdapat garispanduan dan 
farmakoterapi yang berkesan, penjagaan seringkali gagal mencapai tahap amalan 
yang dianggap sebagai yang terbaik. Kajian ini bertujuan untuk menilai pengurusan 
semasa pesakit asma pediatrik berdasarkan adherens kepada garispanduan dan juga 
untuk menilai impak Program Penjagaan Asma (ACP) berstruktur terhadap 
penggunaan sumber dan kos rawatan.  
 
KAEDAH: Kajian semula rekod-rekod perubatan secara retrospektif di 2 buah 
hospital utama untuk menilai tahap adherens kepada garispanduan. Sebelas indikator 
klinikal utama digunakan untuk mengukur adherens. Satu kajian kuasi-eksperimen, 
pre- pasca berserta kumpulan kawalan telah digunakan untuk menilai keberkesanan 
ACP. Pesakit-pesakit di bawah ACP telah menerima penjagaan seperti yang 
disyorkan oleh CPG merangkumi rawatan optima oleh doktor, pendidikan mengenai 
xvii 
 
asma semasa di hospital dan rancangan tindakan asma. Hasilan yang diukur adalah 
kadar kemasukkan semula ke hospital dan kehadiran ke jabatan kecemasan. 
Pengunaan sumber dan kos rawatan juga dinilai. 
 
KEPUTUSAN: Pengurusan dan penjagaan penyakit asma pada keseluruhannya tidak 
mencapai tahap yang disyorkan dalam CPG. Kekurangan ditemui merentasi beberapa 
aktiviti-aktiviti klinikal yang penting. Dalam salah satu hospital, hanya 19.4% 
menerima pendidikan asma, 1.4% mempunyai rancangan tindakan asma, 27.8% 
mempunyai pengkelasan keterukan dan 6.9% telah didiscaj tanpa sebarang ubat 
asma. ACP telah mengurangkan peratusan kanak-kanak yang hadir semula ke jabatan 
kecemasan sebanyak 78% (p < 0.001) berbanding dengan kawalan. Walau 
bagaimanapun, tidak terdapat perbezaan yang signifikan dalam peratusan pesakit 
yang dimasukkan semula ke hospital dalam masa dua bulan berikutan dari 
kemasukan indeks walau pun terdapat penurunan sebanyak 50% didalam kumpulan 
intervensi. Kos purata penyakit asma bagi kumpulan ACP adalah dianggarkan pada 
RM 557.60 (IQR 301.10) berbanding RM 879.00 (IQR 307.70) bagi kumpulan 
kawalan. Peratusan yang paling tinggi adalah kos kemasukan ke hospital iaitu di 
antara 33.3% – 42.4% daripada jumlah kos langsung. 
 
KESIMPULAN: Terdapat banyak peluang untuk memperbaiki penjagaan kanak-
kanak berpenyakit asma. Perlaksanaan ACP telah dikaitkan dengan bertambahnya 
adherens kepada CPG, hasil kesihatan yang lebih baik dan kos rawatan yang lebih 
rendah. Usaha pada masa akan datang untuk memperbaiki pengurusan penyakit asma 
seharusnya disasarkan dalam membaiki komponen-komponen khusus penjagaan 
asma. 
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IMPACT OF AN ASTHMA CARE PROGRAMME ON PROCESS AND COST 
OUTCOME AMONGST CHILDREN WITH ASTHMA IN TWO MAJOR 
HOSPITALS IN MALAYSIA. 
 
ABSTRACT 
 
INTRODUCTION: Childhood asthma is one of the most common chronic diseases. 
Due to its high prevalence, asthma places a considerable economic burden on the 
health care system and society. Optimal management can help to control the disorder 
and various interventions have been put into place based on recommendations of 
clinical practice guidelines (CPGs). However despite the availability of these CPGs 
and effective pharmacotherapy, care often fall short of the accepted best practices. 
This study was aimed at assessing the current management of paediatric patients in 
terms of guideline adherence and to evaluate the impact of a structured Asthma Care 
Programme (ACP) on resource utilisation and cost associated with the management 
of asthma. 
 
METHODS: A retrospective review of medical records at 2 major hospitals to assess 
the level of adherence to the guideline. Eleven key clinical indicators were used to 
measure adherence. A quasi-experimental, pre-post study with control group was 
used to evaluate the effectiveness of the ACP. Patients under the ACP received care 
as recommended by CPGs which include optimal care by physician, asthma 
education during hospitalisation and asthma action plan. The outcome measures were 
xix 
 
the rate of re-hospitalisation and re-attendances to emergency department (ED). 
Resource utilisation and cost of care were also evaluated.  
 
RESULTS: The overall management and care of asthma fell short of the 
recommendations in the CPGs. Deficiencies were found across a range of key 
clinical activities. In one of the hospital, only 19.4% had asthma education, 1.4% has 
asthma action plan, 27.8% had severity classification and 6.9% was discharged 
without any asthma medication. The ACP reduces the proportion of children re-
attending the ED by 78% (p < 0.001) in comparison to the controls. However, there 
was no significant difference in the proportion of patients who were re-admitted in 
the two months following the index admission although there was a 50% reduction in 
the intervention group. The median cost for asthma in the ACP group was estimated 
at RM 557.60 (IQR 301.10) compared to RM 879.00 (IQR 307.70) in the control 
group. The highest proportion was hospitalisation cost between 33.3% - 42.4% of the 
total direct costs. 
 
CONCLUSION: There are opportunities to improve the care for children with 
asthma. Implementation of ACP was associated with an improvement in adherence 
to the CPG, better health outcomes and lower costs of treatment. Future efforts to 
improve asthma management should be targeted to improve the specific components 
of asthma care. 
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CHAPTER 1 
 
INTRODUCTION 
 
This research was conducted in an attempt to assess the current utilisation of 
health care resources in the management of asthma and to evaluate a new asthma 
intervention strategy to improve the quality of asthma care. The aim of this study is 
to propose strategies to improve the health outcome of children with asthma and 
subsequently reducing the cost for asthma management. 
 
Chapter One gives an overview of the research problem and introduces the 
rationale and objectives of the study. The scope of asthma related to the paediatric 
population and the burden of asthma are discussed. The introduction served to lay the 
groundwork for an exploratory study which is to describe the resource utilisation and 
evidence of guideline adherence in the management of asthma. This is followed by a 
prospective quasi-experimental, pre test-post test design (with control group) with 
the intention of evaluating an intervention in the form of a structured Asthma Care 
Programme (ACP) in reducing the resource utilisation for patients with asthma. 
 
1.1 Overview of the research problem 
 
Asthma is one of the most common chronic diseases and has significant 
medical and socioeconomic impact on the society. The World Health Organization 
(WHO) estimates that 300 million people suffer from asthma worldwide and reported 
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that 255,000 died due to asthma in 2005. It is clearly a public health problem in all 
countries especially in low and middle income countries because over 80% of asthma 
death occurs in these countries (WHO, 2006). Childhood asthma is common and its 
prevalence is increasing in most countries of the world. The rising prevalence of 
asthma has been attributed to a number of factors including, change in diet and 
lifestyle, economic development, and increased exposure to allergens and pollutants 
(Weinmayr et al., 2007; Masoli et al., 2004; Ellwood et al., 2001; Stewart et al., 
2001). 
 
The International Study of Asthma and Allergy in Childhood (ISAAC) in 
their worldwide survey found the highest prevalence of asthma occurred in the 
United Kingdom (> 15%), New Zealand (15.1%), Australia (14.7%), the Republic of 
Ireland (14.6%), Canada (14.1%) and followed by the United States (10.9%) while 
the lowest were seen in several Eastern European countries such as Estonia (5.4%), 
Georgia (1.8%) and Greece (1.9%) (Masoli et al., 2004; ISAAC, 1998). 
 
Within the Asia-Pacific region, the prevalence of asthma among children was 
found to be lower when compared to the developed countries. In comparison, the 12-
month prevalence of wheezing was reported as 8.0% in the Asia-Pacific region and 
16.7% in Western Europe (ISAAC, 1998; Kim et al., 1997). In the ISAAC study, the 
prevalence of asthma in countries within the Asia-Pacific region ranges from 1.1% in 
Indonesia to 6.5% in Thailand.  
 
Asthma places a considerable economic burden on the health care systems 
and society. The economic impact due to asthma is substantial. In the United States 
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for example, asthma affects 16 million adults and 1.6 million children. These 
subsequently resulted in 2 million visits to the emergency department (ED), 70,000 
hospitalisations and 5,000 deaths annually (MMWR, 2004). The direct medical cost 
for asthma amounted to USD 3.64 billion and the indirect economic losses was 
estimated at USD 2.6 billion (Weiss et al., 2000). In Europe, according to a survey 
by the European Respiratory Society, the total cost of asthma is estimated at € 17.7 
billion (USD 21.7 billion) per annum. Cost for out-patient is € 3.8 billion (USD 4.6 
billion) followed by anti-asthma drug which is € 3.6 billion (USD 4.4 billion). In-
patients care cost is approximately € 0.5 billion (USD 0.6 billion) and the indirect 
cost in term of productivity losses is estimated at € 9.8 billion (USD 12.0 billion) 
(Braman, 2006).  
 
In this region, the Asthma Insights and Reality in Asia Pacific (AIRIAP) 
study reported an annual per-patient direct costs ranging from USD 108.00 for 
Malaysia to USD 1,010.00 for Hong Kong. Urgent care costs accounted for 18% – 
90% of total per-patient direct costs. The total per-patient direct costs were 
equivalent to 13% of per capita gross domestic product and up to 300% of per capita 
health care spending in some countries (Lai et al., 2006).  
 
Asthma also creates an impact on the individuals, families and their quality of 
life. It affects the lifestyles and activities of those involved and their carer. Data from 
various organizations showed that there is significant morbidity and mortality among 
asthma patients (WHO, 2008; Williams et al., 2003). In children, asthma resulted in 
large proportion of school absenteeism, hospitalisation, emergency visits and time 
lost from work by the carers (Moorman et al., 2007; GINA, 2003). Children with 
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asthma are likely to miss a significant part of their education due to the disease. This 
can have an impact on the performance in school and future opportunities 
(Halterman et al., 2001). 
 
Clinical practice guidelines (CPGs) based on current evidence were developed 
to help improve asthma care and reduce the economic and societal burden. Many 
advances in the science and treatment have been made in recent years. However, 
despite the availability of highly effective medications and CPG for asthma 
management, studies have shown that the treatment and care delivered to the patients 
often fall short of the accepted best practices (Mattke et al., 2007; Diette et al., 2001; 
Finkelstein et al., 2000; Zuckerman et al., 2000; Goodman et al., 1999). This was 
further supported by findings from large surveys in various regions such as the 
Asthma Insights and Reality in Europe (AIRE), the Asthma Insights and Reality in 
Asia-Pacific Study (AIRIAP) and Asthma in America. These reports showed that 
asthma is still under-diagnosed and under-treated (Lai et al., 2003; Rabe et al., 2000). 
This sub-optimal care reflects that the CPG is not effectively implemented and the 
goals of asthma care have not been met (FitzGerald et al., 2006; Rabe et al., 2004; 
Chapman et al., 2001). It remains a major challenge to ensure that children with 
asthma received the appropriate care. Sub-optimally controlled asthma not only puts 
patients at risk, but also has considerable social and economic implications. 
 
Various strategies and approaches have been developed and implemented in a 
variety of settings to address these challenges (Bravata et al., 2007; Butz et al., 2005; 
Homer et al., 2005; Lozano et al., 2004). Poor physician adherence to the guidelines, 
patient‟s non-compliance, inadequate education, incorrect inhaler technique and 
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failure to institute appropriate therapies were among the reasons cited for this gap in 
the management of asthma (Wisnivesky et al., 2008; Basheti et al., 2005; Sawyer & 
Fardy, 2003; Clark & Partridge, 2002; Farquhar et al., 2002; Haby et al., 2002; 
Cabana et al., 2001). 
 
This gap in the management of asthma implies that patients are not receiving 
the optimal benefits from available therapy and health care systems. This sub-
optimal care or gaps represents „Achievable Benefits Not Achieved‟ (ABNA) by the 
health care systems and there are rooms for further improvement in the management 
of asthma (Birnbaum et al., 2006). 
 
In the context of Malaysia, asthma prevalence among children was estimated 
at 4.5% in children (up to 14 years old) and 4.1% in adult (15 years and above). This 
estimates were reported in the Second National Health and Morbidity Survey 
(NHMS II) conducted in year 1996 (IPH, 1996). This figure rose to 7.1% in year 
2006 as reported by the Third National Health and Morbidity Survey (NHMS III) 
(IPH, 2008). Other studies within smaller populations reported a higher figure 
ranging from 10.3% to 13.0% for children in urban populations (Norzila, 2000; 
Azizi, 1990). 
 
Reports from the Health Informatics Centre, Ministry of Health Malaysia, 
showed that in the year 2006 almost 1.3 million patients visited the ED and more 
than 700,000 attended the outpatients department for diseases of the respiratory 
system (MOH, 2007). These represent the main principal causes of attendances at the 
ED and general outpatients department in the government hospitals. The morbidity 
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and expenditures for treating these can represent a substantial economic burden for 
society and health systems. 
 
Limited studies on the economic costs of asthma care are available and the 
economic impact of asthma in Malaysia is not well documented. Reported costs on 
asthma care ranges from USD 15.00 to USD 112.00 per-person. In a study by Safiah 
et al. (1998), the hospitalisation cost for asthma was estimated at RM 395.11 (USD 
112.00) per-patient and it accounted for 78.33% of the total cost. In another study 
conducted in a teaching hospital, Chan et al. (2002) reported a mean treatment cost 
of USD 22.97 and USD 15.56 for treating bronchial asthma in adult and children, 
respectively. Lai et al. (2003), in their AIRIAP study reported that utilisation of 
health care resources for asthma was high as 43.6% of patients were either 
hospitalized or attended ED or made an unscheduled visit for treatment within a year. 
 
The gap in the management of asthma was also reported by local researches. 
Loh and Wong (2005), reported poor adherence to the CPGs by prescribers. Studies 
on knowledge and skills revealed that both children and parents have poor 
knowledge and are not being educated about asthma (Lee & Khoo, 2004; Loh et al., 
2004; Bahari et al., 2003; Fadzil & Norzila, 2002). Parents of children with asthma 
were also reported as having poor skills in utilizing the inhalers and spacers (Aziz et 
al., 2006). 
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1.2 Rationale of the study 
 
Based on evidences which point to an increase in asthma prevalence, its 
economic impact and sub-optimal care, strategies aimed at reducing this burden 
should be further studied. This is particularly important in the context of the 
Malaysian health care system as there are limited published data available compared 
to evidences from other countries. Local studies on asthma among children focus 
mainly on specific components of care such as knowledge, skills, perceptions and 
prescribing patterns. While these studies are important in the management of asthma, 
other approaches aimed at enhancing the management of asthma need to be 
conducted as they are still lacking.  
 
This study is aimed at contributing to fill up this gap in knowledge by 
utilizing a new asthma intervention strategy to improve the management of asthma 
where it was shown to be sub-optimal. In this way, an effective strategy to ensure 
that children with asthma received the appropriate care as recommended by the 
evidence-based guidelines could be determined. 
 
1.3 Purpose of the study 
 
The purpose of this study is to assess the current management of asthma 
amongst hospitalized children and to evaluate the impact of a structured Asthma 
Care Programme (ACP) on resource utilisation and cost associated with the 
management of asthma.  
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Process of care indicators were used to measure the degree of adherence to the 
interrelated components of effective asthma management as recommended by the 
CPG. The impact of a structured Asthma Care Programme (ACP) on the rate of 
readmissions to the hospital and re-attendances to the ED were evaluated.  
 
The ACP consisted of a care programme that incorporates the components of 
asthma care. Patients under the ACP were managed according to their level of 
asthma severity, prescribed the appropriate therapy, provided with an education 
about asthma and a written asthma action plan during their hospitalisation period. 
The educational component mainly focuses on basic facts about asthma, the roles of 
medications, the skills in using inhalers or spacers and the practice of triggers 
avoidance. A pictorial asthma education chart was developed to aid understanding of 
patients and parents on asthma. A written asthma action plan was provided as a guide 
for them to follow when symptoms occured and how to take rescue action. Finally, 
the cost associated with the management of acute asthma in the ED and in-patients 
hospitalisation was estimated. 
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1.4 Specific objectives 
 
The study consisted of two phases with the following specific objectives 
determined for each phases. 
 
Phase 1 – Retrospective review of in-patients data 
 
1.4.1 To evaluate the documentation of evidence in the medical records in relation 
to the requirements of the national guidelines on asthma management, 
 
1.4.2 To describe the pattern of drug utilisation in the treatment of asthma across 
the different severity levels, and 
 
1.4.3 To describe the utilisation of health care resources (hospitalisation and ED 
visits) among children with asthma. 
 
Phase 2 - Prospective in-patients study 
 
1.4.4 To determine the effectiveness of the structured Asthma Care Programme 
(ACP) in reducing the readmission and re-attendance rate, and 
 
1.4.5 To estimate the cost of care for children attending the ED and hospitalized for 
asthma. 
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1.5 Contributions of study findings 
 
The overall result from this study is expected to benefit the children with 
asthma and their carer as it was aimed to improve their health outcome and indirectly 
their quality of life. The intervention would also improve the awareness and ability 
of children to take charge of their own asthma management. This is expected to be 
achieved through the education on self-management and the use of written asthma 
action plan. 
 
The intervention itself would enhance the understanding of the health care 
providers on interventions that improves the quality of asthma care. Hospitals or 
health centres can benefit from the ACP model as it can be incorporated into daily 
practice without much change to the existing delivery system. The strength of the 
ACP is the effective use of time as the education was provided while patients are in 
the hospital for treatment of asthma exacerbation. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
In this chapter, a review of the current literature provides the basis for this 
study. The first section describes asthma and factors influencing its development. 
The current trend in prevalence and burden of asthma is presented. This is followed 
by a review on the management of asthma, the use of evidence-based asthma 
guidelines, their barriers and issues. The final part of the literatures synthesized and 
discussed various strategies related to improving the care for asthma patients. This 
chapter reinforced the rationale of this study and explained how the study builds on 
from earlier work. Asthma situation in Malaysia is described and finally the 
conceptual framework, specific research questions and hypothesis are presented. 
 
2.1 Asthma: Definition and Pathophysiology 
 
Asthma is a chronic inflammatory disorder of the airways. Clinically, asthma 
is characterized by episodic exacerbation of symptoms such as coughs, wheezing, 
chest tightness and breathing difficulties. During an asthma attack, the airways 
become inflamed and swollen. The smooth muscles surrounding the airways 
contract, mucus forms and collects within the airways. The narrowing of the airways 
makes it difficult for the exchange of air in the lungs and this narrowing leads to the 
symptoms and physiological changes in asthma (Canonica, 2006). Several factors 
contribute to the development of airway narrowing and smooth muscle contraction. 
Mucus hypersecretion may lead to luminal occlusion (“mucusplugging”) and is a 
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product of increased mucus secretion and inflammatory exudates. Airway 
hyperresponsiveness is linked to both inflammation and repair of the airways and is 
partially reversible with therapy (Vignola et al., 2001). Asthma attacks can be 
exacerbated by triggers and the most common triggers are respiratory infections 
(Glezen et al., 2000). Other factors that can trigger an attack include allergen 
exposure, environmental pollution, environmental tobacco smoke (ETS), animal 
dander, dust mites, moulds, stress, exercise and changes in weather. Although 
treatment of symptoms can be effective, severe life-threatening attacks can still be 
fatal (McFadden, 2003). 
 
Recent understanding of asthma pathogenesis has resulted in the disease 
being redefined from an episodic airways disease to a chronic inflammatory disorder. 
The Global Initiative for Asthma (GINA) defined asthma as: „Asthma is a chronic 
inflammatory disorder of the airways in which many cells and cellular elements play 
a role. The chronic inflammation causes an associated increase in airway hyper 
responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or early morning. These episodes are 
usually associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously or with treatment’ (GINA, 2003).  
 
This definition describes the basic problem with asthma, which is the 
obstruction to the flow of air due to the narrowing of airways. Based on the 
definition of asthma as an inflammatory disorder, the approach of the current asthma 
management is not only to treat the symptoms but also to suppress the underlying 
inflammatory disorder. This understanding brought about changes in the approach 
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and management of asthma. Therapy to suppress inflammation must be used and 
early intervention with antiinflammatory therapy may modify the disease process. 
Inhaled corticosteroids (ICSs) are considered the most potent and effective long-term 
control medications for asthma. As such the use of corticosteroids has become the 
mainstay in the treatment of asthma (Gupta et al., 2004) and ICSs have now become 
the first-line treatment. Evidences have shown the value of steroids as the foundation 
of asthma therapy (Barnes, 2006; Rowe et al., 2000). 
 
2.2 Asthma: Risk Factors 
 
The probability of an individual developing asthma may increase or decrease 
depending on risk factors. There are a number of factors that influence a person‟s 
risk of developing asthma. The risks factors can be classified as host factors i.e. 
factors within individual such as genetic predisposition, atopy, airway hyper-
responsiveness, gender and race/ethnicity. Another factor, which is modifiable, is the 
environmental factor such as allergens, respiratory infections, tobacco smoke, diet 
and air pollution (indoor and outdoor). 
 
2.2.1 Host factors 
 
Asthma is hereditary and children of asthma subjects are susceptible to 
phenotype associated with asthma. Multiple genes may be involved in different 
ethnic groups and genes associated with serum immunoglobulin E (IgE) level has 
been associated with an increased risk of asthma (Graves et al., 2000; Buchard et al., 
1999; Holgate, 1999; Holloway et al., 1999). Progress in identifying the genes was 
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made when the ADAM-33 gene, a locus on the short arm of chromosome 20 was 
identified and linked to asthma and bronchial hyper-responsiveness (Holgate et al., 
2004; van Eerdewegh et al., 2002).  
 
Atopy is strongly associated with asthma and over 80% of people with asthma 
have evidence of allergic sensitization (Rhodes et al., 2001). The presence of parental 
history of atopy or other allergic disorders (such as eczema, rhinitis) are risk factors 
for persistent asthma in the first six years of life (Martinez et al., 1995). In the early 
childhood, the prevalence of asthma was found to be greater in boys than in girls (de 
Marco et al., 2000). The increase risk in male was associated with higher IgE and 
increased airway tone (Gissler et al., 1999; Sears et al., 1993). At puberty more 
females developed asthma than males resulting in the higher prevalence of female in 
adult asthma (de Marco et al., 2000). The reason for this gender related difference 
however, remains unclear. Studies have found some differences in prevalence of 
asthma between races or ethnicity. Research from United States showed that the 
prevalence of asthma among black children is twice when compared to white 
(McDaniel et al., 2006; Litonjua, 1999; Schwartz et al., 1990). In the UK, people of 
South Asians origins are three times as likely to be admitted to hospital for asthma 
compared to white Europeans (Netuveli et al., 2005). Results from these studies 
suggest that racial disparities in asthma may continue to pose risks for black children. 
Genetic factor may contribute to this condition along with their life style, allergen 
exposure and socio-economic factors (Pearce et al., 2000a).  
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2.2.2 Environmental factors  
Exposure to indoor allergens (house mites, animal dander, cockroaches, 
moulds and yeast) and outdoor allergen (pollens) was associated with increased risk 
for asthma exacerbations (Sporik et al., 1990; Platts-Mills et al., 2000; Sporik & 
Platts-Mills, 2001). However, there is ongoing controversy between allergen 
exposure and the development of the disease. Direct evidence linking allergen 
exposure as a major primary cause of asthma was relatively weak as many other 
factors can contribute to wheezing (Lau et al., 2000; Pearce et al., 2000b). As such 
there is no simple relationship between allergen exposure and asthma. The role of 
allergens in the development of asthma is yet to be fully resolved, but it remains 
important.  
 
Respiratory infections can cause asthma exacerbations in children. The most 
common virus is respiratory syncytial virus (RSV) which causes wheezing. Infants 
with RSV bronchiolitis were associated with development of asthma later in their 
childhood years (Sigurs et al., 2000). RSV is not the only virus associated with 
wheezing as other severe respiratory viral infections have been shown to increase the 
risk of wheezing (Gern, 2000). Although there are evidences to associate viral 
infections and development of asthma, a study by IIIi et al. (2001) found that 
repeated viral infections (other than lower respiratory tract infections) provide a 
protective effect of upper respiratory infections and the risks of developing atopy and 
asthma. 
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The role of diet, particularly breast-feeding and development of asthma has 
been studied and results showed that infants fed on formulas have a higher incidence 
of wheezing compared to those fed on breast milk (Friedman & Zeiger, 2005). 
Increased use of processed foods and decreased intakes of n-3 polyunsaturated fatty 
acid (PUFA) (oily fish) have been suggested as a factor contributing to the increase 
in asthma and atopic disease in some population (Deveraux & Seaton, 2005). 
Omega-3 PUFA has been shown to have anti-inflammatory effects in vitro and 
studies to link it with lower prevalence of asthma have been conducted (Nagakura et 
al., 2000; Weiland et al., 1999). However, a Cochrane review reported that there is 
little evidence that the intake of fish oil will improve asthma control (Thien et al., 
2002).  
 
Exposure to environmental tobacco smoke (ETS) or passive smoking has 
been associated with risk of lower respiratory tract infection in children (Gilliland et 
al., 2000; Ferrence & Ashley, 2000). Maternal smoking during pregnancy and among 
family member was found to increase the risk of developing asthma and wheeze in 
children (Ehrlich et al., 1996). The chemical and carcinogenic constituents of 
tobacco have profound effects on children's health as they may disrupt normal 
biological development (Hogg et al., 2004). Exposure to tobacco smoke is an 
important factor which can affects sensitization, development and aggravation of 
asthma. Apart for ETS, outdoor pollutants from industrial particulate and indoor 
pollutants which include cooking gases, wood fires and materials from building and 
furnishing materials have been linked to asthma (Koenig, 1999). However, the role 
of pollutants in asthma development was said to be inconclusive (Jones, 2000). 
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2.3 Asthma: Burden  
 
2.3.1 Prevalence, morbidity and mortality 
 
Worldwide, asthma affects people of all ages and it was estimated that more 
than 300 million people from all ethnic backgrounds suffer from asthma. Global 
prevalence of asthma ranges from 1% - 18% of the population in different countries 
(Cerveri et al., 1999; ISAAC, 1998). Its prevalence has been increasing in some 
countries but at the same time has stabilized or decline in others (Asher et al., 2006; 
Yan et al., 2005; Garcia-Marcos et al., 2004). It is estimated that there may be an 
additional 100 million people with asthma by 2025 as the proportion of the world‟s 
population living in urban areas are likely to increase (Law et al., 2005; Rosado-
Pinto & Morais-Almedia, 2004). However, there are insufficient data to explain the 
variations of prevalence between the various populations (Bateman et al., 2008). 
 
Asthma can have a major influence on the quality of life of the patients, their 
family and society. Asthma has a substantial impact on the daily functioning and 
emotional well being of a person (Ford et al., 2003). In children, asthma is a major 
cause of school absenteeism, interrupted sleep and limited physical activities (Lai et 
al., 2003; Lenney, 1997). In the United States, children aged 5 - 17 were reported to 
miss 10.5 million school days in year 2008 (Akinbami et al., 2011). Asthma also 
affects the family‟s daily activities as parents or carers may need to take time off 
from work to care for their children. The World Health Organization (WHO) uses the 
term Disability Adjusted Life Years (DALYs) as a measure for the years of „healthy‟ 
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life loss as a measurement of the gap between the current health status and an ideal 
situation where everyone lives into old age free of disease and disability. DALYs 
combine information about morbidity and mortality in terms of healthy years lost. 
WHO has estimated that 15 million DALYs are lost annually due to asthma, 
representing 1% of the total global disease burden (WHO, 2006). 
 
The impact of asthma and treatment on individuals can be expressed by health 
related quality of life (HRQoL), which is broadly defined as an indication of the 
functional impairments (physical, emotional and social) of an individual. Research 
has highlighted that functional impairments are troublesome in children with asthma 
(Juniper et al., 1996; Osman & Silverman, 1996). Children can be troubled as they 
feel isolated and left out by their peers, which can cause them to feel frustrated, 
irritable and angry (Juniper, 2001). The importance of incorporating an assessment 
on HRQoL is now recognised by physicians in managing patients with asthma and 
there are evidences to show a correlation between how patients feel and the clinical 
measures (Juniper et al., 1993; Townsend et al., 1991). In order to obtain a complete 
picture of the patient‟s health status, HRQoL need to be measured together with the 
clinical asthma measures such as peak flow rate, FEV1 and asthma control. Various 
instruments are available such as, the Paediatric Asthma Quality of Life 
Questionnaire (PAQLQ) (Juniper et al., 1996) and the Paediatric Asthma Health 
Outcome Measure (PAHOM) (Chiou et al., 2005) that can be used to measure 
HRQoL. These measurements are necessary as they provide a more comprehensive 
understanding of the impact of asthma on the children‟s quality of life.  
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Asthma deaths are rare in the developed countries, WHO estimated the annual 
worldwide death from asthma at 255,000 annually (WHO, 2006). However, 
mortality rate does not appear to be correlated with prevalence of asthma. Recent 
trends have shown a progressive reduction in mortality rates of 0.23 per 100,000 in 
2004 and 2005 (Wijesinghe et al., 2009). One of the possible reasons for this decline 
is the widespread use of ICS which have been demonstrated to reduce the risks of 
death (Suissa et al., 2000). The risk factors for asthma death depends on the 
following; disease severity, medical care factor both before and during attack, health 
behaviour (such as non-compliance to medication, poor inhaler technique and reduce 
contact with primary care services) and adverse psychosocial factor (Sturdy et al., 
2002; Lanes et al., 2002). 
 
2.3.2 Social and economic burden 
 
Asthma places a considerable financial burden on the health care system and 
society. The burden could be seen from the following aspect: (i) an increased risk for 
early death; (ii) its impact on the quality of life of the children and that of their 
family or carers and; (iii) increased utilisation of health care resources and costs 
associated with the disease. 
 
Studies on the economic costs of asthma in developed countries have revealed 
that the economic cost of asthma is substantial, for both direct cost (such as 
hospitalisation and medication) and indirect cost (such as time lost from work and 
premature death) (Braman, 2006; Cisternas et al., 2003; Weiss et al., 2000). 
Hospitalisation and emergency care account for the largest proportion of the cost of 
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asthma care (Smith et al., 1997). This cost account for more than 60% of asthma 
related health care cost and a significant portion of these expenditures for asthma 
occur in the ED (Stanford et al., 1999). Asthma is the leading cause of 
hospitalisations among children and accounts for a large portion of the direct cost 
(CDC, 2000; Gergen & Weiss, 1990). Children with asthma have almost three times 
the health care expenditures for asthma and more than twice as many ED visits 
compared to children without asthma (Lozano et al., 1999).  
 
In total, per-person annual cost of asthma in the USA averaged USD 4,912.00 
with direct and indirect cost accounting for USD 3,180.00 (65%) and USD 1,732.00 
(35%), respectively (Cisternas et al., 2003). The largest components within direct 
costs were medications USD 1,605.00 (50%), hospital admissions USD 463.00 
(15%) and non-emergency ambulatory visits USD 342.00 (11%). Collectively, for 
children and adults with asthma, the annual projected estimates for asthma was USD 
12.7 billion for direct and indirect costs (Weiss & Sullivan, 2001). In Netherlands the 
annual estimated health care cost per asthmatic patient was USD 293.00 (1993 
dollars) and majority of the costs were attributed to medication use and in-patients 
hospitalisation (Rutten van Molken & Feenstra, 2001). Kiivet et al. (2001) reported 
an annual treatment cost in Estonia amounting to € 118.00 and the biggest 
contributors to the overall costs were medications (63%) and hospitalisations (27%). 
In Switzerland it was reported that direct medical expenditure contributed to 65% of 
the total estimated cost of asthma (Szucs et al., 1999). 
 
Comparing the costs of illness (COI) from six studies in conducted in 
Australia, Sweden, United Kingdom and United States, the authors showed an annual 
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burden per person affected by asthma ranges from USD 326.00 to USD 1,315.00 
(inflated to 1991 US dollars). Out of this amount, approximately 40-50% of the costs 
were attributed to direct medical cost (Weiss & Sullivan, 2001). As seen from these 
studies, there were large variations in the cost of asthma among countries and it is 
difficult to make direct comparison. This is due to differences in the health care 
system, definition of cost and sources for unit cost. However, the direct medical 
expenditures are apparent for each country studied and were consistently found to be 
high. Hospitalisation and unscheduled emergency care were also notably high.  
 
The burden of asthma remains significantly high and it is an ongoing 
challenge to focus on minimizing the impact of asthma. Intervention efforts aimed at 
reducing the burden especially in children remain important. Therefore measures 
taken or aimed at reducing the hospitalisation and emergency visits will have a 
significant impact on the overall cost of the disease. 
 
2.4 Asthma: Management  
 
2.4.1 Diagnosis and assessment of severity 
 
Establishing an accurate diagnosis is essential in the management of asthma. 
The diagnosis of asthma is based on symptoms, patient‟s medical history, physical 
examination and supportive diagnostic test. A correct diagnosis of asthma is essential 
as other conditions such as bronchiectasis, obstructive lung disease, endobroncial 
lesions, foreign bodies, extra or intrathoracic narrowing of the trachea, pneumonia 
and pulmonary emboli can be confused with asthma (Bush, 2007; Levy et al., 2006). 
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Symptoms such as wheeze, chest tightness, shortness of breath and cough are 
suggestive of asthma. More so if these symptoms are recurrent, worsen at night or 
early morning and triggered by exercise, irritants or viral infections. However, the 
signs and symptoms may vary from patients to patients and over period of time 
(Taylor et al., 2008).  
 
Information about patient‟s history should include current symptoms, pattern 
of symptoms, precipitating factors, present treatment, previous hospital admission, 
typical exacerbations, family history of atopy, response to prior treatment and 
prolonged upper respiratory tract infection (URTI) symptoms. Signs of chronic 
illness includes, hyper-expansion of the thorax, wheezing during normal breathing, 
increased nasal secretions, mucosal swelling, sinusitis, and eczema or other signs of 
allergic skin problem are strong indicative of asthma. 
 
The use of spirometry or peak flow meter can enhance the diagnosis of 
asthma. Spirometry which measures the forced expiratory volume in one second 
(FEV1) is the preferred method as objective measures are necessary for accurate 
diagnosis of asthma. Compared to peak flow meter, the measurement of peak 
expiratory flow (PEF) has significant limitations as it depends on the effort and 
technique of the child. Bronchial challenge test (e.g. methacholine) and allergy 
testing (e.g. skin prick) may help to confirm the diagnosis of asthma. Measuring 
inflammatory markers such as eosinophils level (ECP) is another method to diagnose 
asthma but it is not routinely used in clinical practice.  
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The diagnosis of asthma can be more difficult in young children, aged less 
than 5 years as it is often not possible to perform spirometry. The diagnosis has to be 
based mainly on clinical judgement, symptoms and physical assessment. In school 
children (above the age of 7) airway functions and bronchodilator responsiveness 
may be used to confirm the diagnosis as these children are likely to be able to 
perform the test more reliably. Diagnosing asthma in children requires clinical 
judgment as the signs and symptoms vary considerable from patients to patients. 
 
Asthma severity in this section is discussed in the context of previously 
published guidelines by GINA and the National Asthma Education and Prevention 
Program (NAEPP). Asthma severity is defined according to the underlying disease 
process represented by the clinical characteristics before treatment (GINA, 2003; 
NHLBI, 2002).Based on symptoms and level of airflow limitation, the guidelines 
classify asthma into four steps; intermittent, mild persistent, moderate persistent and 
severe persistent as illustrated in Table 2.1. 
 
Severity can be used as a predictor in the limitations of normal daily activities 
and cost of asthma has been shown to be related to level of severity (Antonicelli et 
al., 2004). Patients have more symptoms with increasing severity and the overall cost 
of asthma increases with increasing severity. This cost includes the direct and 
indirect costs (Godard et al., 2002). Other studies have also reported similar findings 
although these studies used retrospective data and different criteria to define severity 
(Weiss et al., 2000; Serra-Batlles et al., 1998; Smith et al., 1997). 
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Table 2.1: Classification of asthma severity by clinical features before 
treatment. 
 
Step 1: Intermittent 
 Symptoms less than once a week 
 Brief exacerbations 
 Nocturnal symptoms not more than twice a month 
 FEV1 or PEF ≥ 80% predicted 
 PEF or FEV1 variability < 20% 
 
Step 2: Mild Persistent 
 Symptoms more than once a week but less than once a day 
 Exacerbations may affect activity and sleep 
 Nocturnal symptoms more than twice a month 
 FEV1 or PEF ≥ 80% predicted 
 PEF or FEV1 variability  20-30% 
 
Step 3: Moderate Persistent 
 Symptoms daily 
 Exacerbations may affect activity and sleep 
 Nocturnal symptoms more than twice a week 
 Daily use of inhaled short-acting ß2 - agonist 
 FEV1 or PEF 60-80% predicted 
 PEF or FEV1 variability  > 30% 
 
Step 4: Severe Persistent 
 Symptoms daily 
 Frequent exacerbations  
 Frequent nocturnal asthma symptoms 
 Limitation of physical activities 
 FEV1 or PEF ≤ 60% predicted 
 PEF or FEV1 variability  > 30% 
Notes: PEF = peak expiratory flow; FEV1 = forced expiratory volume in 1 sec. 
Source: GINA, 2003. 
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In the recent revised version of the GINA and NAEPP guidelines, the concept 
of severity has been refined and expanded to include the concept of current 
impairment and future risk (GINA, 2006; NHLBI, 2007). According to the revised 
guidelines, severity reflects the level and intensity of treatment required to achieve 
control (Taylor et al., 2008). The severity and control of a patient‟s asthma can 
determine the patient‟s level of impairment and future risk. Impairment is defined as 
the frequency and intensity of symptoms, low lung function, and current or recent 
limitations of daily activities. Future risk is identified as the patient‟s risk of 
exacerbations, progressive loss of lung function, or adverse reactions from 
medications. The new guidelines state that patients can still be at high risk for 
frequent exacerbations even if they experience minimal day-to-day effects of asthma.  
 
Once the diagnosis has been established, the focus is then shifted to 
classifying asthma severity so that appropriate therapy can be initiated to achieve 
good control (Taylor et al., 2008). Table 2.2 provides the detail impairment and risk 
criteria that are used in the guidelines. Level of control is based on the most severe 
impairment or risk category.  
 
This classification is important because asthma therapy involves a stepwise 
therapy and appropriate maintenance treatment should correspond to the patient‟s 
severity. Higher doses of therapy can be justified for patients with more severe 
asthma. A reduction in therapy should follow once the asthma control is achieved 
and maintained for a sufficient period of time.  
